Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Landos Biopharma, Inc. (LABP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, August 9, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2023. “We continued to advance and execute the NX-13 Phase 2 clinical program during the second quarter. We have activated sites in the US and are actively recruiting and screening patients,” said Gregory Oakes, President and CEO of..."
05/30/2023 8-K Appointed a new director
Docs: "LANDOS BIOPHARMA, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Landos Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware , does hereby certify as follows: FIRST: The name of the Company is Landos Biopharma, Inc. SECOND: The Company was originally formed as a corporation organized under the jurisdiction of the State of Delaware on January 6, 2017. THIRD: This Amended and Restated Certificate of Incorporation has been duly adopted and approved by the Board of Directors of the Company. The Certificate of Incorporation was last amended and restated by the Amended and Restated Certificate of Incorporation on February 8, 2021. FOURTH: This Amended and Restated Certificate of Incorporation was approved by the holders of the requisite number of ...",
"Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D. NEW YORK, May 30, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee. “Dr. Batycky is an accomplished biopharmaceutical executive and an important addition to Landos’ Board,” said Gregory Oakes, President and CEO of Landos. “Dr. Batycky has a proven track record, and we look forward to her contributions as we execute upon our focused strategy in immunology.” Dr. Batycky brings with her over 25 years of global drug development experience in the biopharmaceutical industry, spanning from ..."
05/25/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENTTOAMENDED AND RESTATED CERTIFICATE OF INCORPORATIONOF",
"Landos Biopharma Announces 1-for-10 Reverse Stock Split NEW YORK, May 25, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10, to be effective as of 5:00 p.m. Eastern Time today, May 25, 2023. The Company’s common stock will begin trading on a split-adjusted basis when the market opens on May 26, 2023 under the existing trading symbol “LABP.” As a result of the reverse stock split, the CUSIP number for the Company’s common stock will now be 515069201. The reverse stock split was previously approved by the stockholders of the Company at the annual meeting of sto..."
05/12/2023 8-K Quarterly results
Docs: "Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. “We continue to execute on a focused strategy for the NX-13 program to maximize value for our shareholders,” said Gregory Oakes, President and CEO of Landos. “Our NEXUS Phase 2 study of NX-13 in UC is designed to advance this important progra...",
"LP 0/4 4/11 4/10 3/11"
03/23/2023 8-K Quarterly results
Docs: "Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025 NEW YORK, March 23, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2022. “Meaningful progress has been made this year as we streamlined our product candidate portfolio to focus on our most promising asset. We believe Landos is uniquely positioned to transfor..."
03/10/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/13/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Investors"
01/05/2023 8-K Quarterly results
01/05/2023 8-K Quarterly results
12/16/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
Docs: "Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks NEW YORK, November 10, 2022 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a business update. “Landos has made significant progress advancing our clinical-stage programs – omilancor, NX-13 and LABP-104,” said Gregory Oakes, President and CEO of Landos. “In August, we announced positive top-line results from our NX-13 Phase 1b trial, which showed a favorable safety and tolerability profile in ulcerative colitis p..."
08/11/2022 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update",
"NX-13 Presentation"
08/03/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial"
06/21/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/26/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
04/06/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/24/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update"
03/10/2022 8-K Quarterly results
01/13/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/15/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
11/10/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/03/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis"
10/28/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Landos Biopharma Announces First Subject Dosed in a Phase 1study of LABP-104 for Systemic Lupus Erythematosus"
10/12/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus"
10/08/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism"
09/22/2021 8-K Quarterly results
09/17/2021 8-K Quarterly results
08/27/2021 8-K Quarterly results
08/26/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy